切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2021, Vol. 10 ›› Issue (06) : 570 -573. doi: 10.3877/cma.j.issn.2095-3232.2021.06.008

临床研究

保留肝右动脉的缩小右半肝切除术治疗肝硬化肝癌
陈骋1, 郑进方1,(), 陈劲松1, 刘俊1   
  1. 1. 570311 海口,海南省人民医院肝胆胰外科
  • 收稿日期:2021-07-22 出版日期:2021-09-23
  • 通信作者: 郑进方
  • 基金资助:
    海南省高等学校科学研究项目(Hnky2019-53)

Reduced right hepatectomy with reserved right hepatic artery for hepatocellular carcinoma complicated with liver cirrhosis

Cheng Chen1, Jinfang Zheng1,(), Jinsong Chen1, Jun Liu1   

  1. 1. Department of Hepatobiliary and Pancreatic Surgery, Hainan General Hospital, Haikou 570311, China
  • Received:2021-07-22 Published:2021-09-23
  • Corresponding author: Jinfang Zheng
引用本文:

陈骋, 郑进方, 陈劲松, 刘俊. 保留肝右动脉的缩小右半肝切除术治疗肝硬化肝癌[J]. 中华肝脏外科手术学电子杂志, 2021, 10(06): 570-573.

Cheng Chen, Jinfang Zheng, Jinsong Chen, Jun Liu. Reduced right hepatectomy with reserved right hepatic artery for hepatocellular carcinoma complicated with liver cirrhosis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2021, 10(06): 570-573.

目的

探讨保留肝右动脉的缩小右半肝切除术治疗肝硬化肝细胞癌(肝癌)患者的安全性和疗效。

方法

回顾性分析2018年7月至2019年4月海南省人民医院行保留肝右动脉的缩小右半肝切除术的8例肝硬化肝癌患者临床资料。患者均签署知情同意书,符合医学伦理学规定。其中男7例,女1例;平均年龄(51±8)岁。术前采用三维重建软件测算全肝体积、残肝体积。分离、结扎门静脉右支,保留肝右动脉,沿左右肝缺血分界线右移1 cm切除右半肝,保留部分肝组织。观察患者围手术期情况。

结果

术前采用三维重建软件模拟右半肝切除,标准肝体积为(993±64)ml,标准右半肝切除的残肝体积为(348±32)ml,占标准肝体积的(35.0±2.3)%;切除平面右移1 cm后残肝体积为(428±34)ml,占标准肝体积的(42.7±1.4)%。所有患者均顺利完成保留肝右动脉的缩小右半肝切除术,术中未发生与操作有关的并发症,保留的肝组织颜色红润。手术时间(224±43)min,术中出血量(220±52)ml。术后肝功能指标呈一过性升高,随后出现下降,术后7 d基本恢复正常。术后腹腔引流液较少,均于术后6 d内拔除腹腔引流管。无发生小肝综合征及肝衰竭。

结论

保留肝右动脉的缩小右半肝切除术是一种安全有效术式,对于肝硬化肝癌的患者可能是一种新的术式选择,其有利于保留更多肝组织,预防术后肝衰竭。

Objective

To evaluate the safety and efficacy of reduced right hepatectomy with reserved right hepatic artery in the treatment of hepatocellular carcinoma (HCC) complicated with liver cirrhosis.

Methods

Clinical data of 8 HCC patients complicated with liver cirrhosis who underwent reduced right hepatectomy with reserved right hepatic artery in Hainan General Hospital from July 2018 to April 2019 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval was received. Among them, 7 patients were male and 1 female, aged (51±8) years on average. The volumes of total liver and residual liver before surgery were measured by 3D reconstruction software. The right branch of the portal vein was separated and ligated. The right hepatic artery was reserved. The right liver was resected 1 cm rightwards from the ischemic line of left and right lobe, and liver tissues were partially preserved. The perioperative conditions of patients were observed.

Results

Preoperatively, 3D reconstruction software was employed to simulate the right hepatectomy. The standard liver volume was (993±64) ml. The residual liver volume after standard right hepatectomy was (348±32) ml, accounting for (35.0±2.3)% of the standard liver volume. The residual liver volume was (428±34) ml after the resection plane was shifted 1 cm to the right side, accounting for (42.7±1.4)% of the standard liver volume. The right hepatectomy with reserved right hepatic artery were successfully completed in all the patients. No intraoperative complications occurred. The preserved liver tissues were found with normal redness. The operation time was (224±43) min and intraoperative blood loss was (220±52) ml. After operation, the parameters related to liver function were increased transiently, and decreased subsequently, and basically restored to normal at postoperative 7 d. After operation, the amount of abdominal drainage was slight, and all the abdominal drainage catheters were removed within postoperative 6 d. No small-for-size syndrome or liver failure occurred.

Conclusions

Reduced right hepatectomy with reserved right hepatic artery is a safe and efficacious surgery, which probably serves as a novel surgical option for HCC patients complicated with liver cirrhosis. It can preserve more liver tissues and prevent postoperative liver failure.

图1 一例肝硬化肝癌患者行保留肝右动脉的缩小右半肝切除术前CT三维重建
表1 肝硬化肝癌患者行保留肝右动脉的缩小右半肝切除围手术期情况(±s
[1]
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J].中国实用外科杂志, 2020, 40(2):121-138.
[2]
Zheng Y, Yang H, He L, et al. Reassessment of different criteria for diagnosing post-hepatectomy liver failure: a single-center study of1 683 hepatectomy[J]. Oncotarget, 2017, 8(51):89269-89277.
[3]
Sheng RF, Yang L, Jin KP, et al. Assessment of liver regeneration after associating liver partition and portal vein ligation for staged hepatectomy: a comparative study with portal vein ligation[J]. HPB, 2018, 20(4):305-312.
[4]
Pandanaboyana S, Bell R, Hidalgo E, et al. A systematic review and meta-analysis of portal vein ligation versus portal vein embolization for elective liver resection[J]. Surgery, 2015, 157(4):690-698.
[5]
Gong WF, Zhong JH, Lu Z, et al. Evaluation of liver regeneration and post-hepatectomy liver failure after hemihepatectomy in patients with hepatocellular carcinoma[J]. Biosci Rep, 2019, 39(8): BSR20190088.
[6]
Chin KM, Allen JC, Teo JY, et al. Predictors of post-hepatectomy liver failure in patients undergoing extensive liver resections for hepatocellular carcinoma[J]. Ann Hepatobiliary Pancreat Surg, 2018, 22(3):185-196.
[7]
Tustumi F, Ernani L, Coelho FF, et al. Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis[J]. HPB, 2018, 20(12):1109-1118.
[8]
Watanabe N, Yamamoto Y, Sugiura T, et al. A predictive scoring system for insufficient liver hypertrophy after preoperative portal vein embolization[J]. Surgery, 2018, 163(5):1014-1019.
[9]
Vyas S, Markar S, Partelli S, et al. Portal vein embolization and ligation for extended hepatectomy[J]. Indian J Surg Oncol, 2014, 5(1):30-42.
[10]
张东欣,姜珊,董家鸿. 大范围肝切除术后肝功能衰竭的研究进展[J].中国现代普通外科进展, 2015(4):295-299.
[11]
Kang D, Schadde E. Hypertrophy and liver function in ALPPS: correlation with morbidity and mortality[J]. Visc Med, 2017, 33(6):426-433.
[12]
Chia DKA, Yeo Z, Loh SEK, et al. ALPPS for hepatocellular carcinoma is associated with decreased liver remnant growth[J]. J Gastrointest Surg, 2018, 22(6):973-980.
[13]
Lopez-Lopez V, Robles-Campos R, Brusadin R, et al. ALPPS for hepatocarcinoma under cirrhosis: a feasible alternative to portal vein embolization[J]. Ann Transl Med, 2019, 7(22):691.
[14]
曹彦龙,李巍. ALPPS治疗剩余肝体积不足的中晚期肝癌的现状[J].中华外科杂志, 2018, 56(4):307-311.
[15]
谭凯,杜锡林,陈安等.术前基于三维可视化技术精准设计肝离断面在ALPPS中的应用[J/OL].中华肝脏外科手术学电子杂志, 2020, 9(2):158-163.
[1] 王春荣, 陈姜, 喻晨. 循Glisson蒂鞘外解剖、Laennec膜入路腹腔镜解剖性左半肝切除术临床应用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 37-40.
[2] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[3] 吴方园, 孙霞, 林昌锋, 张震生. HBV相关肝硬化合并急性上消化道出血的危险因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 45-47.
[4] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[5] 汤海琴, 郭秀枝, 朱晓素, 赵世娣. “隧道法”腹腔镜解剖性左半肝切除术的临床安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 674-677.
[6] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[7] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[8] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[9] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[10] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[11] 严庆, 刘颖, 邓斐文, 陈焕伟. 微血管侵犯对肝癌肝移植患者生存预后的影响[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 624-629.
[12] 秦维, 王丹, 孙玉, 霍玉玲, 祝素平, 郑艳丽, 薛瑞. 血清层粘连蛋白、Ⅳ型胶原蛋白对代偿期肝硬化食管胃静脉曲张出血的预测价值[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 447-451.
[13] 张雯, 宋牡丹, 邓雪婷, 张云. 强化营养支持辅助奥曲肽治疗肝硬化合并食管胃底静脉曲张破裂出血的疗效及再出血危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 456-460.
[14] 朱翔宇, 王建美, 张辉, 叶红英. 无创左心室压力-应变循环技术在左心室功能参数与肝硬化的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 494-498.
[15] 孔凡彪, 杨建荣. 肝脏基础疾病与结直肠癌肝转移之间关系的研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(07): 818-822.
阅读次数
全文


摘要